192 related articles for article (PubMed ID: 2687064)
1. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
[TBL] [Abstract][Full Text] [Related]
2. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.
Scheen A; Castillo M; Jandrain B; Krzentowski G; Henrivaux P; Luyckx AS; Lefèbvre PJ
Diabetes Care; 1984; 7(4):338-42. PubMed ID: 6381007
[TBL] [Abstract][Full Text] [Related]
3. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
Spinas GA; Bock A; Keller U
Diabetes Care; 1985; 8(5):429-35. PubMed ID: 2865093
[TBL] [Abstract][Full Text] [Related]
4. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus.
Orskov L; Alberti KG; Mengel A; Møller N; Pedersen O; Rasmussen O; Seefeldt T; Schmitz O
Diabetologia; 1991 Jul; 34(7):521-6. PubMed ID: 1916058
[TBL] [Abstract][Full Text] [Related]
5. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
[TBL] [Abstract][Full Text] [Related]
6. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.
Krzentowski G; Scheen A; Castillo M; Luyckx AS; Lefèbvre PJ
Diabetologia; 1983 May; 24(5):314-8. PubMed ID: 6347779
[TBL] [Abstract][Full Text] [Related]
7. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus.
Pal BR; Phillips PE; Matthews DR; Dunger DB
Diabetologia; 1992 Jun; 35(6):542-9. PubMed ID: 1612227
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers.
Aarsen RS; Bruining GJ; Grose WF; van Strik R; Lamberts SW; Harris AG
Acta Endocrinol Suppl (Copenh); 1987; 286():45-53. PubMed ID: 2892337
[TBL] [Abstract][Full Text] [Related]
9. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.
Scheen AJ; Krzentowski G; Castillo M; Lefèbvre PJ; Luyckx AS
Diabetologia; 1983 May; 24(5):319-25. PubMed ID: 6135635
[No Abstract] [Full Text] [Related]
10. U-100 insulin gives some protection against metabolic deterioration due to CSII interruption.
Scheen AJ; Henrivaux P; Jandrain B; Lefèbvre PJ
Diabetes Care; 1987; 10(6):707-11. PubMed ID: 3322727
[TBL] [Abstract][Full Text] [Related]
11. Effects of the somatostatin analogue SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man.
Møller N; Petrany G; Cassidy D; Sheldon WL; Johnston DG; Laker MF
Clin Sci (Lond); 1988 Oct; 75(4):345-50. PubMed ID: 3058374
[TBL] [Abstract][Full Text] [Related]
12. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
Castillo MJ; Scheen AJ; Lefèbvre PJ
J Clin Endocrinol Metab; 1996 May; 81(5):1975-8. PubMed ID: 8626867
[TBL] [Abstract][Full Text] [Related]
13. Hepatic glucose production during intraperitoneal and intravenous closed-loop insulin regulation of blood glucose in type 1 (insulin-dependent) diabetic patients.
Robert JJ; Chauvet D; Darmaun D; Leblanc H
Diabetologia; 1993 Nov; 36(11):1185-90. PubMed ID: 8270134
[TBL] [Abstract][Full Text] [Related]
14. Effects of acetylsalicylic acid on blood glucose, plasma FFA, glycerol, 3-hydroxybutyrate, alanine, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetics.
Giugliano D; Luyckx AS; Lefebvre PJ
Diabete Metab; 1980 Mar; 6(1):39-46. PubMed ID: 6989660
[TBL] [Abstract][Full Text] [Related]
15. The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
Montaña E; Fernández-Castañer M; Rosel P; Gómez JM; Vinzia C; Soler J
Diabete Metab; 1990; 16(3):220-5. PubMed ID: 2210017
[TBL] [Abstract][Full Text] [Related]
16. Pulsatile rather than continuous glucagon infusion leads to greater metabolic derangements in insulin-dependent diabetic subjects.
Paolisso G; Sgambato S; Giunta R; Varricchio M; D'Onofrio F
Diabete Metab; 1990; 16(1):42-7. PubMed ID: 2332096
[TBL] [Abstract][Full Text] [Related]
17. The ketosis-resistance in fibro-calculous-pancreatic-diabetes. 1. Clinical observations and endocrine-metabolic measurements during oral glucose tolerance test.
Yajnik CS; Shelgikar KM; Naik SS; Kanitkar SV; Orskov H; Alberti KG; Hockaday TD
Diabetes Res Clin Pract; 1992 Feb; 15(2):149-56. PubMed ID: 1563331
[TBL] [Abstract][Full Text] [Related]
18. The metabolic effects of dopamine in man.
Pernet A; Hammond VA; Blesa-Malpica G; Burrin J; Orskov H; Alberti KG; Johnston DG
Eur J Clin Pharmacol; 1984; 26(1):23-8. PubMed ID: 6143668
[TBL] [Abstract][Full Text] [Related]
19. Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients.
Jimenez JT; Walford S; Home PD; Hanning I; Alberti KG
Diabetologia; 1985 Oct; 28(10):728-33. PubMed ID: 3905470
[TBL] [Abstract][Full Text] [Related]
20. [Lack of benefit from the intermittent administration of insulin in treatment using subcutaneous perfusion pump in type 1 diabetes].
Lilet H; Krzentowski G; Bodson A; Scheen AJ; Lefebvre PJ
Diabete Metab; 1991; 17(3):363-72. PubMed ID: 1884881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
